# Outcome-based annuity payments for potentially curative one-time therapies

Source: https://onco.cc/ideas/idea-fund-pay-for-cure-annuities/  
OnCo record `idea-fund-pay-for-cure-annuities` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Instead of paying hundreds of thousands up front for a CAR-T or gene therapy, the health system would pay in yearly instalments that stop if the cancer comes back, so companies are paid for cures, not attempts.

## Summary

Outcome-based annuities, already used for some gene therapies (for example spinal muscular atrophy and haemophilia contracts in Europe), applied systematically to cell therapies, bispecifics with curative potential and future one-time oncology treatments: payment spread over five years, each instalment contingent on the patient remaining in remission by pre-agreed criteria (imaging, MRD negativity). Payers gain risk-sharing; manufacturers gain higher total payment for real cures and a strong incentive to select patients well and improve durability. Needs a registry to adjudicate outcomes and accounting rules that let payers commit across years.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: Annuity contracts for CAR-T in lymphoma and myeloma lower payer cost per durable remission by at least 20% compared with up-front pricing, without reducing patient access, and manufacturers increase investment in durability (consolidation, MRD-guided retreatment) measurably.
- Rationale: Contracts exist for Zolgensma and haemophilia gene therapies in several countries; oncology has cleaner outcome definitions (relapse) than many indications. Paying for outcomes corrects the current system where a therapy that fails at month six costs the same as one that cures.
- Proposed test: A national payer pilots annuity contracts for CAR-T in one indication with a registry-based remission adjudication, comparing cost per remission-year and access metrics against a control region with up-front pricing.
- Maturity: early-clinical
- Actor: payer

## Sources

- Bottleneck evidence (Incentives reward me-too drugs and marginal gains): Upadhaya et al., PD1/PDL1 inhibitor clinical trial landscape (Nat Rev Drug Discov 2022): https://doi.org/10.1038/d41573-022-00030-4

## Connected records

- ideas: [Hospital-based CAR-T manufacturing at cost through a public network](https://onco.cc/ideas/idea-fund-public-car-t-manufacturing/), [Launch prices indexed to the ESMO benefit scale, revisited when survival matures](https://onco.cc/ideas/idea-fund-mcbs-linked-pricing/)
- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- technologies: [CAR-T cell therapy](https://onco.cc/technologies/car-t/), [MRD / molecular residual disease testing](https://onco.cc/technologies/mrd-testing/)
- drugs: [Axicabtagene ciloleucel](https://onco.cc/drugs/axicabtagene-ciloleucel/), [Ciltacabtagene autoleucel](https://onco.cc/drugs/ciltacabtagene-autoleucel/)
- terms: [Minimal / molecular residual disease (MRD)](https://onco.cc/terms/mrd/), [Real-world evidence](https://onco.cc/terms/real-world-evidence/)
- bottlenecks: [Incentives reward me-too drugs and marginal gains](https://onco.cc/bottlenecks/b-incentive-misalignment/), [Prices and value](https://onco.cc/bottlenecks/b-drug-pricing/)
- key papers: [Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape](https://onco.cc/key-papers/paper-upadhaya-nat-rev-drug-discov/)

---
JSON: https://onco.cc/api/v1/entities/idea-fund-pay-for-cure-annuities.json